Journal of Medicinal Chemistry · 2024 · 10 citations · 41 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsCardiac PharmacotherapyLigand-based DesignPotency OptimizationCardiac Fibrosis ModulationFibrotic ChangeHigh-throughput Screening AssaysLead Compound IdentificationLead Compound ScreeningNrf2 Pathway ActivationStructure - Activity Relationship OptimizationStructure-activity Relationship Modeling
DCN1, a critical co-E3 ligase during the neddylation process, is overactivated in many diseases, such as cancers, heart failure as well as fibrotic diseases, and has been regarded as a new target for drug development. Herein, we designed and synthesized a new class of 1,2,4-triazole-3-thione-based DCN1 inhibitors based the hit HD1 identified from high-throughput screening and optimized through numerous structure–activity-relationship (SAR) explorations. HD2 (IC 50 = 2.96 nM) was finally identified and represented a highly potent and selective DCN1 inhibitor with favorable PK properties and low toxicity. Amazingly, HD2 effectively relieved Ang II/TGFβ-induced cardiac fibroblast activation in vitro, and reduced ISO-induced cardiac fibrosis as well as remodeling in vivo, which was linked to the inhibition of cullin 3 neddylation and its substrate Nrf2 accumulation. Our findings unveil a novel 1,2,4-triazole-3-thione-based derivative HD2, which can be recognized as a promising lead compound targeting DCN1 for cardiac fibrosis and remodeling.
41
Yi‐Chao Zheng, Ying‐Chao Duan, Jinlian Ma et al. · Journal of Medicinal Chemistry · 2013 · 219 citations · Full text
Dcn1 Functions as a Scaffold-Type E3 Ligase for Cullin Neddylation
Thimo Kurz, Yang-Chieh Chou, Andrew Willems et al. · Molecular Cell · 2008 · 192 citations · Full text
Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer
Lihui Li, Mingsong Wang, Guangyang Yu et al. · JNCI Journal of the National Cancer Institute · 2014 · 183 citations
Medicine, Cancer Biology, Oncology +17
Adverse Effects of β-Blocker Therapy for Patients With Heart Failure
Dennis T. Ko, Patricia R. Hebert, Christopher S. Coffey et al. · Archives of Internal Medicine · 2004 · 159 citations
Medicine, Cardiology, Pharmacology +17